BMPs and their clinical potentials

• Published in: BMB reports Vol. 44; no. 10; pp. 619 - 634
• Main Authors: Kim, M.J., Gachon University of Medicine and Science, Incheon, Republic of Korea, Choe, S.Y., Gachon University of Medicine and Science, Incheon, Republic of Korea
• Format: Journal Article
• Language: English
• Published: Korea (South) 생화학분자생물학회 01.10.2011
• Subjects: Animals; BMP; Bone Morphogenetic Proteins - therapeutic use; DIABETE; DIABETES; Humans; Metabolic Diseases - drug therapy; NEOPLASMAS; NEOPLASME; NEOPLASMS; Neoplasms - drug therapy; OVERWEIGHT; Pulmonary hypertension; Signal Transduction - physiology; SOBREPESO; SURPOIDS; TGF-beta; Vascular Diseases - drug therapy; 화학
• ISSN: 1976-6696; 1976-670X
• DOI: 10.5483/BMBRep.2011.44.10.619

Bone morphogenetic protein (BMP) signaling in diseases is the subject of an overwhelming array of studies. BMPs are excellent targets for treatment of various clinical disorders. Several BMPs have already been shown to be clinically beneficial in the treatment of a variety of conditions, including BMP-2 and BMP-7 that have been approved for clinical application in nonunion bone fractures and spinal fusions. With the use of BMPs increasingly accepted in spinal fusion surgeries, other therapeutic approaches targeting BMP signaling are emerging beyond applications to skeletal disorders. These approaches can further utilize next-generation therapeutic tools such as engineered BMPs and ex vivo-conditioned cell therapies. In this review, we focused to provide insights into such clinical potentials of BMPs in metabolic and vascular diseases, and in cancer.